RESUMEN
Botanic gardens play key roles in the development and dissemination of plant information resources. Drivers for change have included progress in information technology, growing public expectations of electronic access and international conservation policy. Great advances have been made in the quantity, quality and accessibility of plant information in digital form and the extent to which information from multiple providers can be accessed through a single portal. However, significant challenges remain to be addressed in making botanic gardens resources maximally accessible and impactful, not least the overwhelming volume of material which still awaits digitisation. The year 2010 represents an opportunity for botanic gardens to showcase their collaborative achievements in delivery of electronic plant information and reinforce their relevance to pressing environmental issues.
Asunto(s)
Acceso a la Información , Biodiversidad , Conservación de los Recursos Naturales/estadística & datos numéricos , Desarrollo de la Planta , Botánica/métodos , Botánica/estadística & datos numéricos , Conservación de los Recursos Naturales/métodos , Ecosistema , Ambiente Controlado , Difusión de la Información , Cooperación Internacional , Internet , Plantas/clasificaciónRESUMEN
Current requirements for control of live viral vaccines, including yellow fever 17D, produced from potentially neurotropic wild-type viruses include tests for neurovirulence in nonhuman primates. We have used yellow fever 17D virus as a live vector for novel flavivirus vaccines (designated ChimeriVax) against dengue, Japanese encephalitis (JE), and West Nile (WN) viruses. For control of these vaccines, it would be preferable to substitute a test in mice for the test in a higher species (monkeys). In this study, we compare the neurovirulence of ChimeriVax vaccine candidates in suckling mice inoculated by the intracerebral (IC) route with graded doses of the test article or yellow fever 17D vaccine as a reference control. Mortality ratio and survival distribution are the outcome measures. The monkey safety test is performed as described for control of yellow fever vaccines. In both mice and monkeys, all chimeric vaccines were significantly less neurovirulent than yellow fever 17D vaccine. The test in suckling mice discriminated between strains of two different vaccines (ChimeriVax-JE and ChimeriVax-DEN1) differing by a single amino acid change, and was more sensitive for detecting virulence differences than the test in monkeys. The results indicate that the suckling mouse test is simple to perform, highly sensitive and, with appropriate validation, could complement or possibly even replace the neurovirulence component of the monkey safety test. The test in infant mice is particularly useful as a means of demonstrating biological consistency across seed virus and vaccine lots.
Asunto(s)
Alternativas al Uso de Animales , Infecciones por Flavivirus/prevención & control , Flavivirus/inmunología , Vacunas Virales/efectos adversos , Animales , Animales Recién Nacidos , Sistema Nervioso Central/virología , Chlorocebus aethiops , Flavivirus/patogenicidad , Haplorrinos , Ratones , Sensibilidad y Especificidad , Células Vero , VirulenciaRESUMEN
Two subjects developed marked elevations in creatine kinase and other serum enzymes associated with mild myalgia during a randomized, double-blind, controlled Phase 1 clinical trial of an investigational live, attenuated vaccine against West Nile virus (ChimeriVax-WN02). One subject had received ChimeriVax-WN02 while the other subject was enrolled in an active control group and received licensed yellow fever 17D vaccine (YF-VAX). Subsequently, the clinical trial was interrupted, and an investigation was begun to evaluate the enzyme abnormalities. As daily serum samples were collected for determination of quantitative viremia, it was possible to define the enzyme elevations with precision and to relate these elevations to physical activity of the subjects, symptoms, and virological and serological measurements. Evaluation of both subjects clearly showed that skeletal muscle injury, and not cardiac or hepatic dysfunction, was responsible for the biochemical abnormalities. This investigation also implicated strenuous exercise as the cause of the apparent muscle injury rather than the study vaccines. As a result of this experience, subjects engaged in future early-stage trials of these live, attenuated viral vaccines will be advised not to engage in contact sports or new or enhanced exercise regimens for which they are not trained or conditioned. The inclusion of placebo control arm (in lieu of or addition to an active vaccine control) will also be useful in differentiating causally related serum enzyme elevations.
Asunto(s)
Enzimas/sangre , Ejercicio Físico/fisiología , Vacunas/efectos adversos , Adulto , Método Doble Ciego , Pruebas de Función Cardíaca , Humanos , Pruebas de Función Hepática , Masculino , Músculo Esquelético/lesiones , Vacunas Virales/efectos adversos , Vacunas Virales/inmunología , Viremia/sangre , Viremia/virología , Replicación Viral , Virus del Nilo Occidental/inmunología , Vacuna contra la Fiebre Amarilla/efectos adversos , Vacuna contra la Fiebre Amarilla/inmunologíaRESUMEN
The availability of ChimeriVax vaccine technology for delivery of flavivirus protective antigens at the time West Nile (WN) virus was first detected in North America in 1999 contributed to the rapid development of the vaccine candidate against WN virus described here. ChimeriVax-Japanese encephalitis (JE), the first live- attenuated vaccine developed with this technology has successfully undergone phase I and II clinical trials. The ChimeriVax technology utilizes yellow fever virus (YF) 17D vaccine strain capsid and nonstructural genes to deliver the envelope gene of other flaviviruses as live-attenuated chimeric viruses. Amino acid sequence homology between the envelope protein (E) of JE and WN viruses facilitated targeting attenuating mutation sites to develop the WN vaccine. Here we discuss preclinical studies with the ChimeriVax-WN virus in mice and macaques. ChimeriVax-WN virus vaccine is less neurovirulent than the commercial YF 17D vaccine in mice and nonhuman primates. Attenuation of the virus is determined by the chimeric nature of the construct containing attenuating mutations in the YF 17D virus backbone and three point mutations introduced to alter residues 107, 316, and 440 in the WN virus E protein gene. The safety, immunogenicity, and efficacy of the ChimeriVax-WN(02) vaccine in the macaque model indicate the vaccine candidate is expected to be safe and immunogenic for humans.